Claims for Patent: 6,511,678

Summary for Patent: 6,511,678

Title:	Controlled release formulation of divalproex sodium
Abstract:	A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Inventor(s):	Qiu; Yihong (Gumee, IL), Bollinger; J. Daniel (Libertyville, IL), Dutta; Sandeep (Waukegan, IL), Cheskin; Howard S. (Glencoe, IL), Engh; Kevin R. (Kenosha, WI), Poska; Richard P. (Mundelein, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	09/748,567
Patent Claims:	1. An oral hydrophilic matrix formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium; b) said divalproex sodium is in admixture with about 20 to about 50 w/w % of a pharmaceutically acceptable hydrophilic polymer selected from the group consisting of polyvinylpyrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate copolymers, polyethyleine oxide, methacrylic acid copolymers, and maleic anhydride/methyl vinyl ether copolymers, and; c) said formulation exhibits the following in-vitro dissolution profile, when measured in a type 2 dissolution apparatus, paddle, at 100 rpm, at a temperature of 37+0.5 C., in 500 ml of 0.1N HCl for 45 minutes, followed by 900 ml of 0.05M phosphate buffer containing 75 mM sodium laurel sulfate, pH 5.5, for the remainder of the testing period: i. no more than about 30% of total valproate is released after 3 hours of measurement in said apparatus; ii. from about 40 to about 70% of total valproate is released after 9 hours of measurement in said apparatus; iii. from about 55 to about 95% of total valproate is released after 12 hour of measurement in said apparatus, and; iv. not less than 85% of total valproate is released after 18 hours of measurement in said apparatus. 2. The formulation according to claim 1 in which said formulation exhibits the following in-vitro dissolution profile: i. from about 15% to about 30% of total valproate is released after 3 hours of measurement in said apparatus; ii. from about 40% to about 70% of total valproate is released after 9 hours of measurement in said apparatus; iii. from about 55% to about 90% of total valproate is released after 12 hours of measurement in said apparatus, and; iv. not less than 88% of total valproate is released after 18 hours of measurement in said apparatus. 3. The formulation according to claim 1 in which said divalproex sodium is present in the amount of from about 45 to about 65 w/w %, based upon the total weight of the formulation. 4. The formulation according to claim 1 which further comprises one or more pharmaceutically acceptable excipients. 5. The formulation according to claim 1, which when ingested orally by healthy human subjects: a. produces a C.sub.max that is statistically significantly lower than the C.sub.max produced by a delayed release enteric coated divalproex sodium tablet given twice daily, when each is determined at steady state in a healthy fasting population; b. produces a C.sub.min that is not statistically significantly different from the C.sub.min produced by said delayed release divalproex sodium tablet, when each is determined at steady state in a healthy fasting population, and; c. said formulation produces an AUC value that is equivalent to the AUC value generated by said divalproex sodium delayed release tablet, when each is determined at steady state in a healthy fasting population. 6. An oral hydrophilic matrix formulation suitable for once-a-day administration comprising: a) from about 40 to about 80 w/w % of divalproex sodium; b) said divalproex sodium is in admixture with about 20 to about 50 w/w % of a pharmaceutically acceptable hydrophilic polymer selected from the group consisting of polyvinylpyrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate copolymers, polyethyleine oxide, methacrylic acid copolymers, and maleic anhydride/methyl vinyl ether copolymers, and c) said formulation exhibits the following in-vitro dissolution profile, when measured in a type 2 dissolution apparatus, paddle, at 100 rpm, at a temperature of 37+0.5 C., in 500 ml of 0.1N HCl for 45 minutes, followed by 900 ml of 0.05M phosphate buffer containing 75 mM sodium laurel sulfate, pH 5.5, for the remainder of the testing period: i. from about 15% to about 27% of total valproate is released after 3 hours of measurement in said apparatus; ii. from about 44% to about 69% of total valproate is released after 9 hours of measurement in said apparatus; iii. from about 59% to about 90% of total valproate is released after 12 hours of measurement in said apparatus, and; iv. not less than 88% of total valproate is released after 18 hours of measurement in said apparatus. 7. A method for the treatment of migraine comprising the administration of a formulation according to claim 1 to a patient in need thereof. 8. A method for the treatment of migraine comprising the administration of a formulation according to claim 6 to a patient in need thereof.